Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Publication
Making the Case for Azathioprine, Methotrexate, and Cyclosporine in Active Vitiligo Management
Published by Frontiers in Medicine (Lausanne) on June 2, 2026
Abstract
Despite growing evidence supporting the efficacy of azathioprine, methotrexate, and cyclosporine in halting vitiligo progression and promoting repigmentation, these agents remain underutilized in routine clinical practice.
Current treatment paradigms overwhelmingly favor corticosteroids as the first-line systemic intervention, especially in cases of rapidly progressive or generalized disease. However, this corticosteroid-centric approach does not adequately address the chronic, relapsing nature of vitiligo and does not offer a sustainable long-term strategy for disease control.
Vitiligo affects approximately 0.76–1.11% of the US population, with up to 40% of cases potentially remaining undiagnosed. The condition imposes a substantial psychosocial burden comparable to other chronic inflammatory diseases, with patients experiencing depression, anxiety, stigmatization, and significant quality-of-life impairment.
Patients often cycle through topical agents and repeated corticosteroid mini-pulses, achieving only temporary stabilization at the cost of accumulating adverse effects. Meanwhile, immunosuppressants with decades of safety data in autoimmune conditions such as lupus, psoriasis, and inflammatory bowel disease remain relegated to off-label or last-resort use in vitiligo.
In our view, this discrepancy between available evidence and clinical practice represents a substantial treatment gap.
We argue that azathioprine, methotrexate, and cyclosporine should no longer be relegated to off-label, last-resort use in vitiligo. Instead, they deserve structured, guideline-level consideration as systemic options for early disease stabilization and maintenance, particularly in patients for whom repeated corticosteroid pulses are unsafe, ineffective, or inaccessible.
In this Opinion, we outline the rationale for this shift and propose a pragmatic path toward integrating these agents into routine care.
Making the Case for Azathioprine, Methotrexate, and Cyclosporine in Active Vitiligo Management
Yan Valle, Julia Sigova, Maria Borodina, Lyailya N. Kayumova, Liliya I. Almakaeva, Vladimir B. Pinegin, Konstantin Lomonosov
FAQOther Questions
- Do Antioxidant Supplements Help Vitiligo?
Do Antioxidant Supplements Help Vitiligo? Short answer Maybe a little. But probably not in the way most people hope. Antioxidant supplements may offer modest support, especially...
- Vitiligo and hearing loss: any connection?
Vitiligo is primarily recognized for causing skin discoloration, but it can also impact melanocytes in unexpected areas, such as the inner ear. This raises questions about wheth...
- Белые пятна на теле? Витилиго?
Гид по Витилиго — ваш компас в лабиринте загадочной болезни и непростых решений. Здесь всё по-честному, по делу и на понятном языке. Вы найдёте здесь: Объяснения, что происходи...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.